EMEA-002765-PIP01-19 - paediatric investigation plan
ribociclib succinate
PIPHuman
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111
P/0218/2020: EMA decision of 17 June 2020 on the granting of a product specific waiver for ribociclib (succinate) (Kisqali), (EMEA-002765-PIP01-19)